NewsRx

Search our medical news database

Cancer Vaccine

IL-1 Trap Shows Positive Results in Study of Patients with Inflammatory Disease

Published in Health and Medicine Week, July 11th, 2005

Regeneron Pharmaceuticals, Inc. announced positive preliminary results from an ongoing pilot study of once-weekly dosing of the Interleukin-1 (IL-1) Trap in patients with CIAS1-associated periodic syndrome (CAPS), a family of autoinflammatory diseases.

All four patients enrolled in the study to date experienced a positive response to a subcutaneous loading dose regimen of the IL-1 Trap, including a sizable reduction in daily patient diary scores and acute phase reactant levels. In the ongoing chronic dosing phase of the study, these patients continue to demonstrate a positive response to the IL-1 Trap.

The study was conducted under a Cooperative...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook